1-6
Original Article
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
Masahiro Tabata, Katsuyuki Kiura, Niro Okimoto, Yoshihiko Segawa and Tetsu Shinkai, et al.
7-17
Original Article
Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin
Zeljko M. Prijovich, Yu-Lin Leu and Steve R. Roffler
19-26
Original Article
Urinary excretion of l
-carnitine and its short-chain acetyl-l
-carnitine in patients undergoing carboplatin treatment
Angelo Mancinelli, S. D’Iddio, R. Bisonni, F. Graziano and P. Lippe, et al.
27-34
Original Article
Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site
Pascal Sève, Tony Reiman, Raymond Lai, John Hanson and Cheryl Santos, et al.
35-43
Original Article
Inhibition of NF-κB-mediated transcription and induction of apoptosis by melampolides and repandolides
Guoyi Ma, Shabana I. Khan, Gloria Benavides, Wolfgang Schühly and Nikolaus H. Fischer, et al.
45-51
Original Article
Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models
Li-mou Zheng, Zujin Li, Lanzhen Liu, Bai Louis Song and Ivan King
53-59
Original Article
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study
Masahiro Tabata, Toshiyuki Kozuki, Hiroshi Ueoka, Katsuyuki Kiura and Shingo Harita, et al.
61-67
Original Article
Phase II trial of 10-EDAM in the treatment of metastatic breast cancer
Garth A. Beinart, Ana M. Gonzalez-Angulo, Kristine Broglio, Debbie Frye and Ronald Walters, et al.
69-79
Original Article
Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells
Chong-Zhi Wang, Xiaoji Luo, Bin Zhang, Wen-Xin Song and Ming Ni, et al.
81-89
Original Article
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)
Roger B. Cohen, Corey J. Langer, George Rajan Simon, Peter David Eisenberg and John Daniel Hainsworth, et al.
91-102
Original Article
Irinotecan–cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line
Jason Zastre, Malathi Anantha, Euan Ramsay and Marcel Bally
103-111
Original Article
The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line
Wei-Ciao Wu, Jenn-Ren Hsiao, Yu-Yan Lian, Chun-Yu Lin and Bu-Miin Huang
113-122
Original Article
The pharmacokinetic behavior of the photosensitizer
meso
-tetra-hydroxyphenyl-chlorin in mice and men
Martijn Triesscheijn, Marjan Ruevekamp, Ruud Out, Theo J. C. Van Berkel and Jan Schellens, et al.
123-128
Original Article
Weekly administration of topotecan–paclitaxel as second-line treatment in ovarian cancer
G. P. Stathopoulos, N. A. Malamos, G. Aravantinos, S. Rigatos and Ch. Christodoulou, et al.
129-134
Original Article
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study
Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Yoon Young Cho and Deok Hwan Yang, et al.
135-141
Clinical Trial Report
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma
Monika K. Krzyzanowska, Ian F. Tannock, Gina Lockwood, Jennifer Knox and Malcolm Moore, et al.
143-150
Clinical Trial Report
Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial
D. Binder, H. Schweisfurth, C. Grah, C. Schäper and B. Temmesfeld-Wollbrück, et al.